Categories AlphaGraphs, Earnings, Health Care
Key highlights from Johnson & Johnson’s (JNJ) Q2 2025 earnings results
Johnson & Johnson (NYSE: JNJ) reported its second quarter 2025 earnings results today.
Reported sales increased 5.8% year-over-year to $23.7 billion. Operational sales growth was 4.6%.
Net earnings grew over 18% to $5.5 billion, or $2.29 per share, compared to last year. Adjusted EPS dropped 1.8% to $2.77.
Revenue and earnings beat expectations.
The company saw sales in the US increase 7.8% to $13.5 billion while international sales grew 3.2% to $10.2 billion.
Sales in the Innovative Medicine segment rose 4.9% to $15.2 billion while sales in the MedTech segment increased 7.3% to $8.5 billion.
For full-year 2025, JNJ expects reported sales to range between $93.2-93.6 billion while adjusted EPS is expected to be $10.80-10.90.
The stock gained 2% in premarket hours on Wednesday.
Listen to the conference calls as they happen. Don't miss a beat! With AlphaStreet Intelligence, you can listen to live calls and interviews as they happen, so you never have to worry about missing out on important information.
Most Popular
CRM Earnings: Salesforce Q3 revenue up 8.6%; earnings beat estimates
Customer relationship management platform Salesforce, Inc. (NYSE: CRM) on Wednesday reported stronger-than-expected earnings for the third quarter of fiscal 2026. Revenues increased 8.6%. Adjusted net income increased to $3.25 per
Cloud Growth and AI Demand in focus as Oracle gears up for Q2 earnings
Technology giant Oracle Corporation (NYSE: ORCL) began the new fiscal year on a mixed note, reporting Q1 FY26 results that grew year over year but fell short of market expectations.
Key takeaways from Macy’s (M) Q3 2025 earnings report
Shares of Macy’s, Inc. (NYSE: M) gained over 1% in mid-day trade on Wednesday after falling earlier in the day despite the company delivering better-than-expected results for the third quarter
